Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.
Trevi Therapeutics, Inc. executive David C. Hastings, the company’s Chief Financial Officer, filed an initial Form 3 ownership report as of 01/08/2026.
The filing indicates that he has no securities beneficially owned in Trevi Therapeutics, with both the non-derivative and derivative securities tables showing no holdings. A power of attorney (Exhibit 24.1) authorizes attorney-in-fact Christopher Galletta to sign the form on his behalf.
Trevi Therapeutics (TRVI) filed its Q3 2025 10‑Q, reporting a net loss of $11.8 million (basic and diluted $(0.08) per share) versus $13.2 million (($(0.13)) a year ago. Operating expenses were $13.9 million, comprised of $10.1 million in R&D and $3.8 million in G&A. Interest income contributed $2.1 million in the quarter.
For the nine months, net loss was $34.4 million. The balance sheet strengthened: cash and cash equivalents $56.9 million and marketable securities $138.1 million at September 30, 2025, supporting total current assets $198.3 million. Stockholders’ equity was $189.8 million and total liabilities were $9.6 million.
Year‑to‑date financing cash inflows were $120.7 million, including $108.2 million from a June 2025 underwritten offering and $10.8 million from warrant exercises. Shares outstanding were 128,215,113 at September 30, 2025; 128,230,134 were outstanding as of October 31, 2025.
Trevi Therapeutics (TRVI) announced financial results for the quarter ended September 30, 2025, and furnished a detailed press release as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference unless specifically referenced.
Trevi Therapeutics, Inc. (TRVI) submitted a Form 144 notice indicating a proposed sale of 108,650 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $1,032,175.00. The proposed approximate sale date is 10/07/2025, and the shares trade on Nasdaq. The filing shows these shares were acquired by an option exercise on 02/26/2023, originally representing 312,855 shares from that exercise.
The filer also reported equity sales totaling 341,505 shares in the prior three months, generating gross proceeds of approximately $2,863,024.00 across multiple dates from 08/27/2025 to 10/06/2025. The shares outstanding figure listed is 121,776,855, making the proposed sale roughly 0.09% of outstanding stock. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Trevi Therapeutics, Inc. submitted a Form 144 disclosing a proposed sale of 40,000 shares of common stock through Stifel Nicolaus & Company with an aggregate market value of $386,716, expected on 10/03/2025. The filing reports 121,776,855 shares outstanding. The securities being sold were originally acquired via an option exercise on 02/26/2023 totaling 312,855 shares with a reported payment date of 02/16/2023. The filer also disclosed recent open-market sales by Lisa Delfini totaling 312,855 shares during Aug–Sep 2025, including a 155,000-share sale on 09/09/2025 that generated $1,256,787.
Trevi Therapeutics (TRVI) filed a Form 144 reporting a proposed sale of common stock through Stifel Nicolaus & Company. The notice lists 312,855 shares to be sold with an aggregate market value of $2,532,530, against total shares outstanding of 121,776,855. The approximate date of sale is 08/27/2025 and the securities exchange is Nasdaq.
The filing discloses how the shares were acquired: 65,712 shares from restricted stock units dated 02/15/2023 (paid 02/16/2023 in cash) and 259,576 shares from an option exercise dated 02/26/2023 (paid 02/16/2023 in cash). No securities were reported sold by the person in the past three months. The filer signs the standard representation that they do not possess nonpublic material adverse information about the issuer.
Trevi Therapeutics reports that Chief Financial Officer Lisa Delfini will end her employment and resign as CFO on August 22, 2025. The company states that her resignation is not due to any disagreement over operations, policies, or practices. In line with its Executive Separation Benefits and Retention Plan, Trevi has agreed to provide her with separation benefits, conditioned on signing a severance and release agreement that includes a general release of claims, a non-disparagement commitment, and reaffirmation of existing confidentiality, non-solicitation, and non-compete obligations.
As of the effective date of her departure, President and Chief Executive Officer Jennifer L. Good will also serve as the company’s principal financial officer on an interim basis until a new principal financial officer is designated.
Viking Global Investors and affiliated entities report beneficial ownership of 7,505,694 shares of Trevi Therapeutics (TRVI), representing 5.9% of the common stock. The holdings consist of 1,543,000 shares directly owned by two affiliated entities (1,033,810 by VGOP and 509,190 by VGOD) and 5,962,694 shares issuable upon exercise of pre-funded warrants exercisable at $0.001 per share. The filing clarifies the ownership chain through multiple Delaware and Cayman entities and notes shared voting and dispositive power among the reporting persons, including O. Andreas Halvorsen, David C. Ott and Rose S. Shabet. The statement affirms these securities were not acquired to change or influence control of the issuer.
NEA amendments report current holdings and a dilution-driven decrease in stake. The filing discloses that New Enterprise Associates and affiliated reporting persons collectively beneficially own 15,074,080 shares of Trevi Therapeutics common stock, representing 12.0% of the outstanding class on the basis stated in the filing. NEA 16 is shown as the record owner of 10,421,428 shares and as holding warrants exercisable for 3,703,704 shares; NEA 18 VGE holds 948,948 shares. The ownership figures reflect shared voting and dispositive power among the reporting entities and individuals.
The amendment explains the decrease in the percentage ownership as resulting from an increase in the number of shares outstanding, and reiterates that the Funds acquired the shares for investment purposes. The filing states there are no present plans by the reporting persons to pursue corporate actions such as board changes, asset sales, or extraordinary transactions, and notes that no transactions were effected by the reporting persons in the last 60 days. Exhibits include the joint filing agreement and a power of attorney.